Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice

A. E. Takemori; C. B. Yim; D. L. Larson; P. S. Portoghese

doi:10.1016/0014-2999(90)90445-C

Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice

A. E. Takemori, C. B. Yim, D. L. Larson, P. S. Portoghese

Medicinal Chemistry

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A series of naltrexamine bivalent ligands, compounds with two naltrexamine pharmacophores separated by a spacer which contains a variable number of glycyl units flanking a succinyl group, were synthesized and evaluated in vivo in mice. These compounds possessed long-acting agonist and especially antagonist activities. The bivalent ligands, 2 and 3 displayed antinociceptive activity that lasted > 4h. Compound 1, a bivalent ligand and 4, the monomer, antagonized the antinociceptive effect of morphine for a week after a single injection i.c.v. The long duration of action may be due to entrapment of these ligands in the central nervous system. These compounds may give future insights into the design of long-acting agonists and antagonists.

Original language	English (US)
Pages (from-to)	285-288
Number of pages	4
Journal	European Journal of Pharmacology
Volume	186
Issue number	2-3
DOIs	https://doi.org/10.1016/0014-2999(90)90445-C
State	Published - Sep 21 1990

Bibliographical note

Funding Information:
Bivalent ligands, compounds that contain two recognition sites joined through a connecting spacer, have attracted considerable interest as molecular probes because some of them display considerable selectivity for a single opioid receptor type. For example, the triethylenedioxy derivative of fl-naltrexamine (TENA) (Portoghese and Takemori, 1985), binaltorphimine (BNI) and nor-BNI (Portoghese et al., 1987) are bivalent ligands selective for K opioid receptors. Previously, a series of bivalent ligands with fl-naltrexamine as the 1 This investigation was supported by USPHS grants from the National Institute on Drug Abuse. Studies in this report were carried out in accordance with the Declaration of Helsinki and/or with the guide for the care and use of laboratory animals as adopted and promulgated by the Na-tional Institutes of Health. Correspondence to: A.E. Takemori, Department of Pharmacology, 3-249 Millard Hall, University of Minnesota, 435 Delaware St. S.E., Minneapolis, MN 55455 U.S.A.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Keywords

(Long acting)
Analgesia
Antinociception
Naltrexamine bivalent ligands
μ-Opioid receptor antagonists

Access

10.1016/0014-2999(90)90445-C

OpenUrl availability

Full text

Cite this

@article{6ef0b5ff1a2b4e578e7671707497fd7f,

title = "Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice",

abstract = "A series of naltrexamine bivalent ligands, compounds with two naltrexamine pharmacophores separated by a spacer which contains a variable number of glycyl units flanking a succinyl group, were synthesized and evaluated in vivo in mice. These compounds possessed long-acting agonist and especially antagonist activities. The bivalent ligands, 2 and 3 displayed antinociceptive activity that lasted > 4h. Compound 1, a bivalent ligand and 4, the monomer, antagonized the antinociceptive effect of morphine for a week after a single injection i.c.v. The long duration of action may be due to entrapment of these ligands in the central nervous system. These compounds may give future insights into the design of long-acting agonists and antagonists.",

keywords = "(Long acting), Analgesia, Antinociception, Naltrexamine bivalent ligands, μ-Opioid receptor antagonists",

author = "Takemori, {A. E.} and Yim, {C. B.} and Larson, {D. L.} and Portoghese, {P. S.}",

note = "Funding Information: Bivalent ligands, compounds that contain two recognition sites joined through a connecting spacer, have attracted considerable interest as molecular probes because some of them display considerable selectivity for a single opioid receptor type. For example, the triethylenedioxy derivative of fl-naltrexamine (TENA) (Portoghese and Takemori, 1985), binaltorphimine (BNI) and nor-BNI (Portoghese et al., 1987) are bivalent ligands selective for K opioid receptors. Previously, a series of bivalent ligands with fl-naltrexamine as the 1 This investigation was supported by USPHS grants from the National Institute on Drug Abuse. Studies in this report were carried out in accordance with the Declaration of Helsinki and/or with the guide for the care and use of laboratory animals as adopted and promulgated by the Na-tional Institutes of Health. Correspondence to: A.E. Takemori, Department of Pharmacology, 3-249 Millard Hall, University of Minnesota, 435 Delaware St. S.E., Minneapolis, MN 55455 U.S.A. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1990",

month = sep,

day = "21",

doi = "10.1016/0014-2999(90)90445-C",

language = "English (US)",

volume = "186",

pages = "285--288",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

number = "2-3",

}

TY - JOUR

T1 - Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice

AU - Takemori, A. E.

AU - Yim, C. B.

AU - Larson, D. L.

AU - Portoghese, P. S.

N1 - Funding Information: Bivalent ligands, compounds that contain two recognition sites joined through a connecting spacer, have attracted considerable interest as molecular probes because some of them display considerable selectivity for a single opioid receptor type. For example, the triethylenedioxy derivative of fl-naltrexamine (TENA) (Portoghese and Takemori, 1985), binaltorphimine (BNI) and nor-BNI (Portoghese et al., 1987) are bivalent ligands selective for K opioid receptors. Previously, a series of bivalent ligands with fl-naltrexamine as the 1 This investigation was supported by USPHS grants from the National Institute on Drug Abuse. Studies in this report were carried out in accordance with the Declaration of Helsinki and/or with the guide for the care and use of laboratory animals as adopted and promulgated by the Na-tional Institutes of Health. Correspondence to: A.E. Takemori, Department of Pharmacology, 3-249 Millard Hall, University of Minnesota, 435 Delaware St. S.E., Minneapolis, MN 55455 U.S.A. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1990/9/21

Y1 - 1990/9/21

N2 - A series of naltrexamine bivalent ligands, compounds with two naltrexamine pharmacophores separated by a spacer which contains a variable number of glycyl units flanking a succinyl group, were synthesized and evaluated in vivo in mice. These compounds possessed long-acting agonist and especially antagonist activities. The bivalent ligands, 2 and 3 displayed antinociceptive activity that lasted > 4h. Compound 1, a bivalent ligand and 4, the monomer, antagonized the antinociceptive effect of morphine for a week after a single injection i.c.v. The long duration of action may be due to entrapment of these ligands in the central nervous system. These compounds may give future insights into the design of long-acting agonists and antagonists.

AB - A series of naltrexamine bivalent ligands, compounds with two naltrexamine pharmacophores separated by a spacer which contains a variable number of glycyl units flanking a succinyl group, were synthesized and evaluated in vivo in mice. These compounds possessed long-acting agonist and especially antagonist activities. The bivalent ligands, 2 and 3 displayed antinociceptive activity that lasted > 4h. Compound 1, a bivalent ligand and 4, the monomer, antagonized the antinociceptive effect of morphine for a week after a single injection i.c.v. The long duration of action may be due to entrapment of these ligands in the central nervous system. These compounds may give future insights into the design of long-acting agonists and antagonists.

KW - (Long acting)

KW - Analgesia

KW - Antinociception

KW - Naltrexamine bivalent ligands

KW - μ-Opioid receptor antagonists

UR - http://www.scopus.com/inward/record.url?scp=0025182332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025182332&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(90)90445-C

DO - 10.1016/0014-2999(90)90445-C

M3 - Article

C2 - 1963149

AN - SCOPUS:0025182332

SN - 0014-2999

VL - 186

SP - 285

EP - 288

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 2-3

ER -

Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this